Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984172 | 0.90 | TP53 (0.42) | L3MBTL1NPC1LMNAALDH1A1GAA | |
| SCHEMBL4991698 | 0.84 | L3MBTL1 (0.53) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL7215103 | 0.84 | L3MBTL1 (0.68) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5664145 | 0.81 | LTA4H (0.40) | L3MBTL1NPC1ALDH1A1LTA4HHTT | |
| SCHEMBL5664934 | 0.79 | CHRM2 (0.40) | L3MBTL1NPC1ALDH1A1HPGDTSHR | |
| SCHEMBL3856122 | 0.77 | TP53 (0.52) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL5664357 | 0.76 | BCHE (0.41) | L3MBTL1NPC1LTA4H | |
| SCHEMBL4986792 | 0.74 | NPC1 (0.47) | L3MBTL1NPC1LMNAALDH1A1HPGD | |
| SCHEMBL4981470 | 0.73 | MITF (0.42) | L3MBTL1NPC1LMNAALDH1A1MAPT | |
| SCHEMBL6401625 | 0.72 | ZDHHC20 (0.39) | LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| EP-1716137-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | Pfizer Products Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1578725-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005080373-A1 | SUBSTITUTED QUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004056777-A1 | MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132745-A1 | Microsomal triglyceride transfer protein inhibitor | MTTP, CETP, APOB | L3MBTL1 3319/4885NPC1 27/4885LMNA 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.